TY - JOUR
T1 - The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
AU - Cohen, Idan
AU - Campisi-Pfinto, Salvatore
AU - Rozenberg, Orit
AU - Colodner, Raul
AU - Bar-Sela, Gil
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/4/6
Y1 - 2023/4/6
N2 - Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BNT162b2- dose and had the breakthrough infection, and those who received the 4th-BNT162b2-dose and had no breakthrough infection. Anti-SARS-CoV-2 immunoglobulin-G (IgG) levels of the control group exhibited a rapid decrease over time, whereas IgG titers of patients with breakthroughinfections or patients vaccinated with the 4th-BNT162b2-dose were considerably elevated, consistent with the capacity of the second booster to induce anti-SARS-CoV-2 IgG levels. Additionally, oncology patients' humoral immune response was significantly greater after breakthroughinfection than in response to the 4th dose of BNT162b2.
AB - Since January 2022 in Israel, high-risk populations with underlying health conditions were advised to receive a fourth dose of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We monitored vaccine-induced immunity among oncology patients undergoing systemic anti-cancer therapy before and after the 4th-BNT162b2-dose. Three groups of patients were included in the study: those who received 3rd-BNT162b2-dose and had no breakthrough infection (control), those who received 3rd-BNT162b2- dose and had the breakthrough infection, and those who received the 4th-BNT162b2-dose and had no breakthrough infection. Anti-SARS-CoV-2 immunoglobulin-G (IgG) levels of the control group exhibited a rapid decrease over time, whereas IgG titers of patients with breakthroughinfections or patients vaccinated with the 4th-BNT162b2-dose were considerably elevated, consistent with the capacity of the second booster to induce anti-SARS-CoV-2 IgG levels. Additionally, oncology patients' humoral immune response was significantly greater after breakthroughinfection than in response to the 4th dose of BNT162b2.
KW - BNT162b2 vaccine
KW - SARS-CoV-2
KW - cancer patient
UR - http://www.scopus.com/inward/record.url?scp=85152172055&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyad003
DO - 10.1093/oncolo/oyad003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36856804
AN - SCOPUS:85152172055
SN - 1083-7159
VL - 28
SP - e225-e227
JO - Oncologist
JF - Oncologist
IS - 4
ER -
